U.S. patent application number 10/684151 was filed with the patent office on 2004-05-06 for physiologically acceptable aqueous solutions and methods for their use.
Invention is credited to Segall, Judith M., Segall, Paul E., Sternberg, Hal, Waitz, Harold D..
Application Number | 20040086578 10/684151 |
Document ID | / |
Family ID | 27557057 |
Filed Date | 2004-05-06 |
United States Patent
Application |
20040086578 |
Kind Code |
A1 |
Segall, Paul E. ; et
al. |
May 6, 2004 |
Physiologically acceptable aqueous solutions and methods for their
use
Abstract
Artificial plasma-like solutions and methods for their use are
provided. The subject solutions include: electrolytes and an
oncotic agent. The subject solutions find use in a variety of
applications, particularly in those applications where at least a
portion of a host's blood volume is replaced with a blood
substitute.
Inventors: |
Segall, Paul E.; (Berkeley,
CA) ; Sternberg, Hal; (Berkeley, CA) ; Waitz,
Harold D.; (Berkeley, CA) ; Segall, Judith M.;
(Berkeley, CA) |
Correspondence
Address: |
BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK
CA
94025
US
|
Family ID: |
27557057 |
Appl. No.: |
10/684151 |
Filed: |
October 10, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10684151 |
Oct 10, 2003 |
|
|
|
09530006 |
Apr 20, 2000 |
|
|
|
6680305 |
|
|
|
|
09530006 |
Apr 20, 2000 |
|
|
|
PCT/US97/19964 |
Oct 31, 1997 |
|
|
|
09530006 |
Apr 20, 2000 |
|
|
|
08886921 |
Jul 2, 1997 |
|
|
|
5945272 |
|
|
|
|
08886921 |
Jul 2, 1997 |
|
|
|
08780974 |
Jan 9, 1997 |
|
|
|
08780974 |
Jan 9, 1997 |
|
|
|
08364699 |
Dec 28, 1994 |
|
|
|
08364699 |
Dec 28, 1994 |
|
|
|
08253384 |
Jun 3, 1994 |
|
|
|
5702880 |
|
|
|
|
08253384 |
Jun 3, 1994 |
|
|
|
08133527 |
Oct 7, 1993 |
|
|
|
08133527 |
Oct 7, 1993 |
|
|
|
08071533 |
Jun 4, 1993 |
|
|
|
5407428 |
|
|
|
|
Current U.S.
Class: |
424/717 ;
514/557; 514/60 |
Current CPC
Class: |
A01N 1/0205 20130101;
A61K 33/10 20130101; A61K 38/36 20130101; A01N 1/0221 20130101;
A61K 9/0026 20130101; A61K 38/38 20130101; A01N 1/02 20130101; A61K
45/06 20130101; A61K 33/14 20130101; A61K 38/42 20130101; A61K
33/10 20130101; A61K 2300/00 20130101; A61K 33/14 20130101; A61K
2300/00 20130101; A61K 38/36 20130101; A61K 2300/00 20130101; A61K
38/38 20130101; A61K 2300/00 20130101; A61K 38/42 20130101; A61K
2300/00 20130101 |
Class at
Publication: |
424/717 ;
514/060; 514/557 |
International
Class: |
A61K 031/718; A61K
031/19; A61K 033/00 |
Claims
What is claimed is:
1. A physiologically acceptable aqueous solution comprising:
electrolytes; a dynamic buffering system; and at least one oncotic
agent; wherein said solution comprises at least two of magnesium, a
sugar in an amount of not more than about 50 mM and a medium or
high molecular weight oncotic agent, and further wherein said
solution does not comprise a biological buffer.
2. The solution according to claims 1, wherein said dynamic
buffering system comprises a carboxylic acid, salt or ester
thereof.
3. The solution according to claims 1, wherein said dynamic
buffering system further comprises bicarbonate.
4. The solution according to claim 1, wherein said solution further
comprises a cryoprotective agent.
5. The solution according to claim 1, wherein said oncotic agent is
a polysaccharide.
6. The solution according to claim 5, wherein said polysaccharide
is a hydroxyethyl starch.
7. The solution according to claim 6, wherein said hydroxyethyl
starch is a medium molecular weight hydroxyethyl starch.
8. The solution according to claim 6, wherein said hydroxyethyl
starch is a high molecular weight hydroxyethyl starch.
9. The solution according to claim 1, where said electrolytes
comprise sodium, potassium, calcium, chloride ion and
magnesium.
10. The solution according to claim 1, wherein said solution
further comprises a clotting factor.
11. A physiologically acceptable aqueous solution comprising:
electrolytes; a dynamic buffering system; and at least one oncotic
agent, wherein said at least one oncotic agent is a medium or high
molecular weight hydroxyethyl starch; wherein said solution does
not comprise a biological buffer.
12. The solution according to claim 11, wherein said dynamic
buffering system comprises a carboxylic acid, salt or ester
thereof.
13. The solution according to claim 11, wherein said dynamic
buffering system further comprises bicarbonate.
14. The solution according to claim 11, wherein said solution
further comprises a cryoprotective agent.
15. The solution according to claim 11, wherein said hydroxyethyl
starch is a medium molecular weight hydroxyethyl starch.
16. The solution according to claim 11, wherein said hydroxyethyl
starch is a high molecular weight hydroxyethyl starch.
17. The solution according to claim 11, where said electrolytes
comprise sodium, potassium, calcium, chloride ion and
magnesium.
18. The solution according to claim 11, wherein said solution
further comprises a clotting factor.
19. In a method where an aqueous composition is introduced into the
circulatory system of a host or portion thereof, the improvement
comprising using the physiologically acceptable aqueous solution
according to claim 1.
20. In a method where an aqueous composition is introduced into the
circulatory system of a host or portion thereof, the improvement
comprising using the physiologically acceptable aqueous solution
according to claim 11.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No.
09/530,006 filed as Application No. PCT/US97/19964 on Oct. 31,
1997; which application is a continuation-in-part of U.S.
application Ser. No. 08/886,921 filed Jul. 2, 1997 and now
abandoned; which application is a continuation of U.S. application
Ser. No. 08/780,974 filed Jan. 9, 1997 and now abandoned; which
application is a continuation of U.S. application Ser. No.
08/364,699 filed Dec. 28, 1994 and now abandoned; which application
is a continuation-in-part of U.S. application Ser. No. 08/253,384
filed Jun. 3, 1994 and now issued as U.S. Pat. No. 5,702,880; which
application is a continuation-in-part of U.S. application Ser. No.
08/133,527 filed Oct. 7, 1993 and now abandoned; which application
is a continuation-in-part of U.S. application Ser. No. 08/071,533
filed Jun. 4, 1993 and now issued as U.S. Pat. No. 5,407,428; the
disclosures of which are herein incorporated by reference.
INTRODUCTION
[0002] 1. Technical Field
[0003] The technical field of this invention is plasma-like
solutions which may be used to substitute for the blood or plasma
of a subject.
[0004] 2. Background of the Invention
[0005] Physiologically acceptable solutions find use in a variety
of different applications in the medical, biomedical research and
related fields. For example, physiologically acceptable solutions
find use as plasma substitutes in surgical applications which
require the replacement of significant amounts of blood plasma
volume. Such applications include treatments for blood lost during
surgery or trauma, or when a tissue, organ, group of organs or an
entire subject needs to be maintained at a hypothermic or frozen
state. Such applications also include applications in which a
patient's blood is flowed through an external device, such as a
cardiopulmonary bypass machine, where the extra circulatory volume
space resulting from attachment of the patient's circulatory system
to the device must be filled with a compatible blood substitute,
i.e., blood volume expander.
[0006] Physiologically acceptable solutions suitable for use as
plasma expanders/substitutes must be able to mix freely with blood
without unacceptably compromising its components, such as creating
precipitates which significantly block flow in small vessels,
destroying an unacceptable portion of its formed elements (cells,
platelets), introducing agents or creating water, ionic or
molecular imbalances destructive to body cells and tissues, or
causing harmful physiologic activities such as inappropriate
acceleration or inhibition of heartbeat, nerve conduction or muscle
contraction, and the like.
[0007] The first plasma substitute solutions employed were derived
from mammalian blood. Although such solutions have been used with
success, because such solutions are derived from natural blood,
they can contain various pathogenic substances, such as viral
pathogens such as HIV, Hepatitis B, and other pathogens, e.g.,
prions such as those associated with Cruetzfeldt-Jakob disease, and
the like. As such, use of blood substituted and plasma substitute
solutions derived from natural blood are not free of
complication.
[0008] As such, a variety of synthetic blood and plasma substitute
solutions have been developed which are prepared from non-blood
derived components. Although synthetic plasma-like solutions have
found increasing use in a variety of applications, no single
solution has proved suitable for use in all potential
applications.
[0009] Accordingly, there is continued interest in the development
of new physiologically acceptable aqueous solutions that are
suitable for use as plasma substitutes. Of particular interest is
the development of solutions that are suitable for use in
hypothermic surgical applications, such as cardiac surgery and the
like. Also of interest is the development of solutions that are
terminally heat sterilizable.
[0010] Relevant Literature
[0011] Various physiologically acceptable solutions, particularly
blood substitute solutions, and methods for their use are described
in U.S. Pat. Nos. RE 34,077; 3,937,821; 4,001,401; 4,061,736;
4,216,205; 4,663,166; 4,812,310; 4,908,350; 4,923,442; 4,927,806;
5,082,831; 5,084,377; 5,130,230; 5,171,526; 5,210,083; 5,274,001;
5,374,624; 5,407,428 and 5,514,536.
[0012] Additional references describing physiologically acceptable
solutions, including blood substitute solutions include: Bishop et
al., Transplantation (1978) 25:235-239; Messmer et al.,
Characteristics, Effects and Side-Effects of Plasma Substitutes, pp
51-70; Rosenberg, Proc.12th Congr. Int. Soc. Blood Transf. (1969);
Spahn, Anesth. Analg. (1994) 78:1000-1021; Biomedical Advances In
Aging (1990) (Plenum Press) Chapter 19; Wagner et al., Clin. Pharm.
(1993) 12:335; ATCC Catalogue of Bacteria & Bacteriophages
(1992) p 486; and 06-3874-R8-Rev. May (1987) Abbott Laboratories,
North Chicago, Ill. 60064, USA.
[0013] Additional references describing various applications of
such solutions, including hypothermic applications, include: Bailes
et al., Cryobiology (1990) 27:615-696(pp 622-623); Belzer et al.,
Transplantation (1985) 39:118-121; Collins, Transplantation
Proceedings (1977) 9:1529; Fischer et al., Transplantation (1985)
39:122; Kallerhoff et al., Transplantation (1985) 39:485; Leavitt
et al., FASEB J. (1990) 4: A963; Ross et al., Transplantation
(1976) 21:498; Segall et al. FASEB J. (1991) 5:A396; Smith, Proc.
Royal Soc. (1956) 145: 395; Waitz et al., FASEB J. (1991) 5.
[0014] Lehninger, Biochemistry (2.sup.nd Ed., 1975), pp 829ff
provides a review of blood and its constituents.
SUMMARY OF THE INVENTION
[0015] Physiologically acceptable aqueous solutions and methods for
their use are provided. The subject solutions include: electrolytes
and an oncotic agent. The solutions find use in a variety of
applications, particularly in applications in which at least of
portion of a host's blood volume is replaced with a blood
substitute solution.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
[0016] Physiologically acceptable aqueous solutions and methods for
their use are provided. The subject solutions include: electrolytes
and an oncotic agent. In certain embodiments, the solutions include
at least one of calcium ion and a dynamic buffering system. The
solutions may be used in a variety of applications and are
particularly suited for use in applications where at least a
portion of a host's blood is replaced with a substitute solution.
In further describing the invention, the aqueous solutions
themselves will be described first in greater detail followed by a
discussion of various representative applications in which the
solutions find use.
[0017] Before the subject invention is further described, it is to
be understood that the invention is not limited to the particular
embodiments of the invention described below, as variations of the
particular embodiments may be made and still fall within the scope
of the appended claims. It is also to be understood that the
terminology employed is for the purpose of describing particular
embodiments, and is not intended to be limiting. Instead, the scope
of the present invention will be established by the appended
claims.
[0018] It must be noted that as used in this specification and the
appended claims, the singular forms "a," "an," and "the" include
plural reference unless the context clearly dictates otherwise.
Unless defined otherwise all technical and scientific terms used
herein have the same meaning as commonly understood to one of
ordinary skill in the art to which this invention belongs.
[0019] The aqueous solutions of the subject invention are
physiologically acceptable, by which is meant that the solutions
may be introduced into the vasculature of a host without inherently
causing a toxic reaction. The solutions will have a pH ranging from
about 4 to 10, usually from about 4.5 to 9 and more usually from
about 5 to 8.5.
[0020] In one embodiment, the solutions will include a plurality of
electrolytes, including: sodium ion, chloride ion, potassium ion
and calcium ion. The sodium ion concentration of the solutions will
range from about 70 to 160, usually from about 110 to 150, and in
some embodiments from 130 to 150 mM. The concentration of chloride
ion in the solution will range from about 70 to 170, usually from
about 80 to 160, more usually from about 100 to 135 and in some
embodiments from about 110 to 125 mM. The concentration of
potassium ion will range from the physiological to
subphysiological, where by "physiological" is meant from about 3.5
to 5, usually from about 4 to 5 mM, and by "subphysiological" is
meant from about 0 to 3.5, usually from about 2 to 3 mM, where in
many embodiments of the invention, the amount of potassium ion will
range from about 1 to 5, usually from about 2 to 3 mM, where in
certain embodiments, the amount of potassium ion may be higher than
5 mM and range as high as about 5.5 mM or higher, but will usually
not exceed about 5.5 mM. The solutions will also include calcium
ion in an amount ranging from about 0.5 to 6.0 mM, and in many
embodiments will range from about 0.5 to 4.0, usually from about
2.0 to 2.5 mM, but in certain embodiments will range from about 4.0
to 6.0, usually from about 4.5 to 6.0 mM. The solutions may further
include magnesium. When present, the magnesium ion will range from
about 0 to 10 mM, usually from about 0.3 to 3.0 and more usually
from about 0.3 to 0.45 mM.
[0021] In one embodiment, the solutions will include sodium ion and
potassium ion, and optionally calcium ion. The sodium ion
concentration of the solutions will range from about 70 to 160,
usually from about 110 to 150, and in some embodiments from 130 to
150 mM. The concentration of potassium ion will range from the
physiological to subphysiological, where by "physiological" is
meant from about 3.5 to 5, usually from about 4 to 5 mM, and by
"subphysiological" is meant from about 0 to 3.5, usually from about
2 to 3 mM, where in many embodiments of the invention, the amount
of potassium ion will range from about 1 to 5, usually from about 2
to 3 mM, where in certain embodiments, the amount of potassium ion
may be higher than 5 mM and range as high as about 5.5 mM or
higher, but will usually not exceed about 5.5 mM. Optionally, the
solutions may further include calcium ion. When present, the
calcium ion will range from about 0.5 to 6.0 mM, and in many
embodiments will range from about 0.5 to 4.0, usually from about
2.0 to 2.5 mM, but in certain embodiments will range from about 4.0
to 6.0, usually from about 4.5 to 6.0 mM.
[0022] The solutions may also include a dynamic buffering system,
where the term dynamic buffering system is used to refer to one or
more reagents that work in combination to keep the pH of the
solution in a certain range in an in vivo environment. Preferably,
the reagent members of the dynamic buffering system are normal
biological components that maintain in vivo biological pH. The
dynamic buffering system concept rests on the discovery by the
inventors that compounds with no intrinsic buffering capacity in
the biological range, such as lactate, acetate, or gluconate which
are capable of being metabolized in vivo, act with other solution
components to maintain a biologically appropriate pH in an animal,
even at hypothermic temperatures and at essentially bloodless
conditions. The dynamic buffering system of the present invention
depends in part on oxygenation and removal of carbon dioxide
(CO.sub.2). The dynamic buffer of the invention has no or
substantially no ability to act as a buffer outside of a biological
system, i.e., a dynamic buffer maintains pH in the biological range
in vivo but not in a cell free environment.
[0023] A critical component of the dynamic buffering system of the
invention is a carboxylic acid, salt or ester thereof. By a
carboxylic acid, salt or ester thereof is meant a compound having
the general structural formula RCOOX, where R is an alkyl, alkenyl,
or aryl, branched or straight chained, containing 1 to 30 carbons
which carbons may be substituted, and preferably one of the carbon
chains that compose the carbon chain of lactate, acetate,
gluconate, citrate, pyruvate, or other biological metabolites; and
X is hydrogen or sodium or other biologically compatible ion
substituent which can associate at the oxygen position.
[0024] Optionally, the dynamic buffering system may further include
a source of bicarbonate, usually sodium bicarbonate (NaHCO.sub.3).
When present, the concentration of NaHCO.sub.3 will range from
about 0.1 mM to 40 mM, usually from about 0.5 mM to 30 mM, and more
usually from about 1 mM to 10 mM.
[0025] The solution of the present invention does not include a
conventional biological buffer. By "conventional buffer" is meant a
compound which in solution, in vitro, maintains pH at a particular
range. By "conventional biological buffer" is meant a compound
which in a cell-free system maintains pH in the biological range of
7-8. Examples of conventional biological buffers include
N-2-Hydroxyethylpiperazine-N'-2-h- ydroxypropanesulfonic acid
(HEPES), 3-(N-Morpholino) propanesulfonic acid (MOPS),
2-([2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]amino)ethanesulfonic acid
(TES),
3-[N-tris(Hydroxy-methyl)ethylamino]-2-hydroxyethyl]-1-pipera-
zinepropanesulfonic acid (EPPS), Tris[hydroxymethyl]-aminomethane
(THAM), and Tris[hydroxymethyl]methyl aminomethane (TRIS).
Conventional biological buffers have a pK in the physiological
range and function most efficiently in this range. Therefore, these
buffers function independently of normal biological processes and
are most potent in cell-free systems.
[0026] The absence of a conventional biological buffer in the
solution of the invention confers several important medical
advantages. For example, lower concentrations of buffers consisting
of normal biological components are required to maintain in vivo
pH, compared to conventional biological buffers. Conventional
biological buffers may also pose toxicity problems. Further, the
absence of a biological buffer allows the solution to be terminally
heat sterilized. Generally, medical solutions are preferred to be
terminally heat sterilized prior to use in a patient. The term
"terminally heat sterilized" or "heat sterilized" as used herein
refers to the process involving heating a solution to about
120.degree. C. for 15 minutes under pressure, i.e., maintaining
heat and pressure conditions for a period of time sufficient to
kill all or substantially all bacteria and inactivate all or
substantially all viruses in the solution. This procedure is
normally performed in an autoclave, and is also known as
"autoclaving". The purpose of heat sterilization is to kill
possible infectious agents present in the solution. Infectious
agents are known to tolerate temperatures up to 100.degree. C. It
is generally considered by the art that heating a solution under
pressure to 120.degree. C. for about 15 minutes is sufficient to
insure sterility.
[0027] The solutions will also include an oncotic agent. The
oncotic agent is included of molecules whose size is sufficient to
prevent its loss from the circulation by readily traversing the
fenestrations of the capillary bed into the interstitial spaces of
the tissues of the body. As a group, oncotic agents are exemplified
by blood plasma expanders. Compounds finding use as oncotic agents
in the subject invention may be natural or synthetic, and will
usually be polymeric compositions having an average molecular
weight of at least about 40,000, usually at least about 100,000 and
more usually at least about 200,000, where oncotic agents having a
molecular weight of 300,000 or higher may find use. Examples of
oncotic agents suitable for use in the solution of the present
invention include proteinaceous compounds, such as albumin, e.g.,
human serum albumin, and cross-linked or high molecular weight
hemoglobin, polysaccharides such as glucan polymers, and the like;
organic polymers, e.g., PVP, PEG, etc.; and the like; where
non-antigenic polysaccharides are preferred;
[0028] Polysaccharides that find use as oncotic agents in the
subject solutions include hydroxyethyl starches, hydroxymethyl
alpha (1 4) or (1 6) polymers, D-glucose polymers, e.g., dextrans
having an alpha (1 6) linkage, cyclodextrins,
hydroxypropylstarches, hydroxyacetylstarches, and the like.
[0029] Hydroxyethyl starches are of particular interest for certain
embodiments of the subject invention. The average molecular weight
of hydroxyethyl starches finding use in the subject invention may
range from 10,000 to 1,000,000 d or higher, where the molecular
weight will typically range from about 40,000 to 1,000,000, usually
from about 100,000 to 900,000, and more usually from about 200,000
to 800,000 d. Preferred are compositions in which the average
molecular weight of the hydroxyethyl starch oncotic agent ranges
from about 50,000 to 1,000,000, usually from about 100,000 to
900,000 and more usually from about 200,000 to 800,000 d. The
degree of substitution will range from about 4 to 10, where in
certain embodiments, the degree of substitution will range from 7
to 10, in other embodiments will range from 4 to 5, and in other
embodiments will range from 6 to 7. Therefore, one class of
preferred solutions will include a hydroxyethyl starch with between
about 6 and 7 hydroxyethyl groups for every 10 glucose units.
Another class of preferred solutions will include between about 4
and 5 hydroxyethyl groups for every 10 glucose units. Yet another
class of preferred solutions will include between about 7 and 8
hydroxyethyl groups for every 10 glucose units.
[0030] A particularly preferred oncotic agent is Hetastarch (McGaw,
Inc.), an artificial colloid derived from a waxy starch composed
almost entirely of amylopectin with hydroxyethyl ether groups
introduced into the alpha (1 4) linked glucose units and having a
molar substitution of about 0.7 hydroxyethyl groups/glucose unit.
The average molecular weight of hydroxyethyl starch is 480,000 with
a range of 400,000 to 550,000 and with 80% of the polymers falling
in the range of 30,000 to 2,400,000 d. The colloid properties of a
6% solution (wt/wt) of Hetastarch approximates that of human serum
albumin.
[0031] Another particularly preferred oncotic agent is Pentastarch,
which has a molar substitution of about 0.45 hydroxyethyl
groups/glucose unit and an average molecular weight range (as
measured by the HPSEC method as reported in PDR 1996) of from about
150,000 to 350,000 d, with 80% between 10,000 and 2,000,000 d.
[0032] Another particularly preferred oncotic agent is
"Hexastarch," which has a molar substitution of about 0.64
hydroxyethylgroups/glucose unit and an average molecular weight of
about 220,000.
[0033] In certain embodiments, the hydroxyethyl starch will be a
select fraction of the initial hydroxyethyl starch source,
particularly a select size fraction, where generally the fraction
will be at least one of the fraction having an average molecular
weight of less than about 1,000,000 daltons or the fraction having
an average molecular weight of greater than about 50,000 daltons.
Conventional fractionation means may be used to prepare such
fractions.
[0034] The concentration of oncotic agent in the solution is
sufficient to achieve (when taken together with chloride salts of
sodium, calcium and magnesium, organic ion from the organic salt of
sodium and hexose sugar discussed above) colloid osmotic pressure
approximating that of normal human serum, about 28 mm Hg.
Generally, the amount of oncotic agent in the solution will range
from about 0.5 to 30, usually from about 1 to 25 and more usually
from about 2 to 8%. Where the oncotic agent is a hydroxyethyl
starch, the amount present in the solution will range from about 1
to 30, usually from about 2 to 15 and more usually from about 4 to
8%.
[0035] The solution may further include one or more different
optional agents which may be included in the solution to make the
solution suited for a particular application. One optional agent
that may be included, and usually is included, is sugar. The sugar
will generally be a simple hexose sugar, such as glucose, fructose
and galactose, of which glucose is preferred. In the preferred
embodiment of the invention nutritive hexose sugars are used and a
mixture of sugars can be used. The sugar is typically, though not
necessarily, present in the solution in a physiological amount. By
the term "physiological amount" or "physiological levels" is meant
the concentration of sugar is in a range between 2 mM and 50 mM
with concentration of glucose of 5 mM being preferred. At times, it
is desirable to increase the concentration of hexose sugar in order
to lower fluid retention in the tissues of a subject. Thus the
range of hexose sugar may be expanded up to about 50 mM or even
above, but usually not above 60 and more usually not above 55 mM,
if necessary to prevent or limit edema in the subject under
treatment, except where the agent is present as a cryoprotective
agent.
[0036] The solutions of the present invention may include a blood
clotting factor able to accelerate or promote the formation of a
blood clot. Preferred blood clotting factors for use in the
solution of the invention include vitamin K, Factors I, II, V, VII,
VIII, VIIIC, IX, X, XI, XII, XIII, protein C, von Willebrand
factor, Fitzgerald factor, Fletcher factor, and a proteinase
inhibitor. The concentration of the blood clotting factor is
determined by one skilled in the art depending on the specific
circumstances of treatment. For example, generally when vitamin K
is administered, its concentration will be sufficient to deliver
5-10 mg to the patient.
[0037] The solutions of the present invention may include an
oxygen-carrying component in a concentration sufficiently low so as
not to be toxic to the subject. The oxygen carrying component will
usually be present in a sufficient amount to deliver enhanced
oxygen to the tissues of a subject without resulting in toxicity to
the subject. A "sufficient amount" of an oxygen-carrying component
is an amount allowing a resting subject with an unimpaired
circulation and physiology to survive and recover from trauma,
illness or injury. In normal humans at normal body temperature,
this is at least 5-6 ml O.sub.2/100 ml of intravascular fluid.
Oxygen-carrying components include hemoglobin extracted from human
and non-human sources, recombinant hemoglobin, hemocyanin,
chlorocruorin and hemerythrin, and other naturally occurring
respiratory pigments extracted from natural sources or made by
recombinant DNA or in vitro methods. These compounds may be
modified by a number of means known to the art, including by
chemical crosslinking or covalent bonding to polyethylene glycol
group(s). When the oxygen-carrying component is hemoglobin, it is
preferably present in the concentration range of between about
20-200 g/l.
[0038] The solutions may further include one or more cryoprotective
agents, where by cryoprotective agent is meant any agent that
preserves the structural integrity of tissue under hypothermic,
e.g., sub-zero, conditions, where in certain embodiments the
cryoprotective agent will be an agent that disrupts, at least to a
partial extent, the ordered crystal arrangement of water molecules
in a manner such that the freezing point of the aqueous solution
comprising the cryoprotective agent is lowered as compared to the
freezing point of an analogous solution that does not include a
cryoprotective agent. Cryoprotective agents of interest include:
alcohols, particularly low molecular weight aliphatic alcohols,
usually C1 to C6 alcohols, more usually C1 to C4 alcohols, such as
methanol, ethanol, and the like; polyols, including linear,
branched and cyclic polyols, usually low molecular weight aliphatic
polyols, including diols, triols, and other polyols, such as sugars
(described in greater detail below) where polyols of particular
interest include diols, such as ethylenediol, propanediol,
butanediol, triols, e.g., glycerol, and the like; sugars, including
erythrose, threose, ribose, arabinose, xylose, lyxose, allose,
atrose, glucose, mannose, gulose, idose, galactose, talose,
erythrulose, ribulose, xylulose, psicose, fructose, sorbose,
tagatose and disaccharides, e.g., sucrose, lactose and maltose,
where glucose is particularly preferred; other agents such as
timethylamine, trimethylamine oxide (TMAO), DMSO, urea, formamide,
dimethylformamide and the like; clathrates, silicon comprising
agents, such as silanes and the like, fluorocarbon compounds and
derivatives thereof, etc.; where the cryoprotective agent may be
forced into solution by pressure and/or a suitable surfactant agent
may be employed, where such surfactant agents are known to those of
skill in the art. Such agents will typically be present in amounts
sufficient to provide the desired cryoprotective effect, where the
particular amount of the agent will depend on the particular agent
employed. When the agent is a polyol, e.g., a diol, it will
generally be present in amounts ranging from about 0.2 to 1 M or 0
to 30%. With respect to propanediol, in particular a range of 0.2 M
to 0.6 M is preferred and a concentration of about 0.4 M
propanediol is most preferred. 1,2-propanediol is preferred as the
adduct to the solution used for low temperature organ and donor
preservation according to the invention, although 1,3-propanediol
may be used. For TMAO, TMAO will be present in the solution in a
final concentration in a range between 0.2 M and 7 M. When glycerol
is employed, it will be present in a concentration ranging from
about 0 to 40%, usually from about 5 to 30%, and more usually 5 to
20%. When DMSO is employed, it will be present in amounts ranging
from about 0 to 40%, usually from about 5 to 30%, and more usually
from about 5 to 20%. When a sugar is employed (particularly
glucose), the sugar ranges between about 0.6 M to about 1.4 M, with
1.0 M being preferred for certain embodiments.
[0039] In preparing the subject solutions, the various constituents
may be combined at substantially the same time, or added
sequentially, as may be convenient. The solutions may be terminally
heat sterilized as described above. As also described above, the
solutions may further include agents that should not be terminally
heat sterilized, such as a source of bicarbonate, where the
bicarbonate participates in the dynamic buffering system. In such
instances, the sodium bicarbonate will be added as a sterile
solution to a pre-autoclaved "base solution." Similarly, when it is
desirable to add a blood clotting factor or oxygen-carrying
component, the blood clotting factor or oxygen-carrying component
is added as a sterile solution to the autoclaved base solution.
[0040] For purposes of description of the invention, the mixture
according to the invention has been discussed and will continue to
be discussed in terms of an aqueous solution. From the following
description of the invention, it is expected that one of ordinary
skill in the art would be enabled to provide the mixture as a dry
mixture and make the adjustments to amounts of sodium chloride and
organic salt of sodium as necessary to accommodate the amounts of
sodium chloride found in normal saline solution, which may be used
as a diluent for the dry mixture according to the invention.
[0041] The subject solutions find use in a variety of different
applications. The subject solutions find particular use in
applications where it is desired to replace at least a portion of a
host's (or tissue or organ thereof) circulating blood volume with a
substitute solution, where such applications include: surgical
procedures, including procedures involving a reduction in the
temperature of a host from the host's normal body temperature; as a
blood substitute; to maintain physiological integrity following
death; as a cold preservation agent for tissue or organ; in
regional chemoperfusion; and the like.
[0042] The solution may be used as a circulating solution in
conjunction with oxygen or hyperbaric oxygen at normal body
temperatures or during procedures when the subject's body
temperature is reduced significantly below the subject's normal
temperature. For example, during surgical procedures and in cadaver
organ donation at low temperatures, the subject's blood may be
replaced with the cold circulating solution of the invention, where
the solution may be circulated for a time to perfuse and maintain
the subject and its organs intact during the procedure.
[0043] The solution of the present invention may be administered
intravenously or intra arterially to a euthermic subject which is
placed in a pressurized atmosphere of increased oxygen
concentration up to 100% oxygen or to such a subject undergoing a
procedure during which the subject's body temperature is reduced
significantly below the subject's normal temperature whether or not
hyperbaric oxygen is used. While the solution is being administered
to and circulated through the subject, various agents such as
cardioplegic agents may be administered either directly into the
subject's circulatory system, administered directly to the
subject's myocardium, or added to the circulating solution of the
present invention. These components are added to achieve desired
physiological effects such as maintaining regular cardiac
contractile activity, stopping cardiac fibrillation or completely
inhibiting contractile activity of the myocardium or heart
muscle.
[0044] Cardioplegic agents are materials that cause myocardial
contraction to cease and include anesthetics such as lidocaine,
procaine and novocaine and monovalent cations such as potassium ion
in concentrations sufficient to achieve myocardial contractile
inhibition. Concentrations of potassium ion sufficient to achieve
this effect are generally in excess of 15 mM, and magnesium may
also be present in amounts in excess of about 0.5 mM.
[0045] During revival of a subject (after a period of subnormal
temperature or cryogenic maintenance using the solution according
to the invention to maintain the subject) the subject may be
reinfused with a mixture of the solution according to the invention
along with blood retained from the subject or obtained from blood
donors. As the subject is warmed, whole blood is infused until the
subject achieves an acceptable hematocrit, generally exceeding
hematocrits of about 20%. When an acceptable hematocrit is
achieved, perfusion is discontinued and the subject is revived
after closure of surgical wounds using conventional procedures.
[0046] In general, the solution according to the invention is
administered using an intravenous line (when the subject is at
normal temperature) or to a chilled subject using a pumped
circulating device such as a centrifugal pump, roller pump,
peristaltic pump or other known and available circulatory pump. The
circulating device is connected to the subject via cannulae
inserted surgically into appropriate veins and arteries. When the
solution is administered to a chilled subject, it is generally
administered via an arterial cannula and removed from the subject
via a venous cannula and discarded, stored or circulated.
[0047] The solution may be used in a variety of surgical settings
and procedures. It may be useful in delicate neurosurgery where
clear surgical fields are imperative and reduced central nervous
system activity may be desirable and achieved by performing the
procedure on a patient whose core temperature and/or cerebral
temperature has been substantially reduced.
[0048] The solution may be used to maintain a subject (which has
lost a significant amount of blood, e.g., 20% to 98% of its blood)
at normal body temperatures in a pressurized environment at
increased oxygen concentration above atmospheric oxygen tension up
to 100% oxygen. The subject is maintained in a high oxygen
concentration, either continuously or periodically, until enough
blood components can be synthesized by the subject to support life
at atmospheric pressure and oxygen concentration. The solution
according to the invention may be used to maintain a subject at
temperatures lower than normal body temperature and at a reduced
rate of metabolism after traumatic life threatening injury until
appropriate supportive or corrective surgical procedures can be
performed. In addition the solution may be used to maintain a
patient having a rare blood or tissue type until an appropriate
matching donor can be found and replacement blood units or other
organ can be obtained.
[0049] Surprisingly it has been discovered that it is possible to
replace substantially all of a mammalian subject's circulating
blood with the solution according to the invention and to maintain
the subject alive without reinfusing blood into the subject.
Substantially all of a mammalian subject's circulating blood is
considered to be replaced when the subject's hematocrit drops below
10%. Hematocrit may be lower than 10% if O.sub.2 is provided to the
subject, or substantially lower than 10% in a hyperbaric O.sub.2
chamber. The solution according to the invention can of course be
used to maintain a subject having a hematocrit in excess of
10%.
[0050] The procedure for replacing substantially all of a mammalian
subject's circulating blood may be carried out with the mammalian
subject's body temperature being maintained at its substantially
normal temperature. In addition the procedure may be carried out
with cooling of the subject and reduction of the mammalian
subject's body temperature below that of its normal temperature.
Cooling may be accomplished by chilling the subject in an ice bath,
ice-salt slurry, or cooling blanket. The subject may be further
cooled by chilling the solution according to the invention prior to
perfusing the subject with the solution.
[0051] In the procedure according to the invention for replacing
substantially all of a mammalian subject's circulating blood, it is
preferred that the subject is chilled and perfused with the
solution, using an arterial catheter to deliver the solution to the
subject's circulatory system and a venous catheter to remove blood
and the perfusate from the subject. Substantially all of the
subject's circulating blood is removed in this manner as determined
by measurement of the hematocrit of the effluent from the venous
catheter. When substantially all of the subject's circulating blood
is removed, perfusion may be stopped.
[0052] In addition, the procedure for replacing substantially all
of the subject's blood may be carried out with the aid of
hyperbaric O.sub.2. The subject is placed in a hyperbaric chamber
pressurized with oxygen at concentrations exceeding 20%, preferably
100% oxygen. The pressure of the hyperbaric chamber is maintained
during most of the procedure in a range between 0.5 pounds per
square inch over atmospheric pressure to pressures up to about
twice atmospheric pressure. In one embodiment, the procedure is
performed with the subject in a hyperbaric chamber at hyperbaric
pressures of about 0.07 to about 2 atmospheres over ambient
pressure (0.5-30 pounds per square inch [psi]) with 100% oxygen. If
necessary, the pressure of the hyperbaric chamber may be reduced to
atmospheric pressure during wound closure. The subject is
subsequently maintained at hyperbaric pressure at high oxygen
concentration. The pressure is gradually reduced to a lower
pressure but one still hyperbaric. Preferably the pressure is
maintained below 10 psi to about 5 psi for a number of hours to
several days. Subsequently, the pressure is again gradually lowered
below 1 psi and preferably to about 0.5 psi and is maintained at
this pressure for an additional period of time up to a day or
more.
[0053] The solution may also be used to maintain the physiological
integrity of an organ donor subject immediately after the
occurrence of brain death. The subject can be chilled, the
subject's blood removed and replaced with a circulating solution
maintained below 37.degree. C., or while circulating cold solution
according to the invention. Through this use of the solution,
ischemia of vital organs can be minimized. By circulating cold
solution according to the invention through the subject's
circulatory system at low temperature with or without placing the
subject in a hyperbaric oxygen chamber, vital organs can be
maintained for longer periods of time, thus maximizing the number
of organs that can be effectively used from one donor for potential
transplant recipients.
[0054] In another aspect of the invention, it has been discovered
that by using certain adducts, particularly propanediol and high
concentration glucose to augment the solution, it may be possible
to reduce the temperature of donor organs, and in particular donor
hearts, below the freezing point of water (0.degree. C.) and
recover them from freezing in a useful state, i.e., a state capable
of maintaining coordinated cardiac contraction. Furthermore by
using the solution according to the invention with such adducts, it
has been possible to reduce the temperature of intact mammalian
subjects below the freezing point of water (0.degree. C.) and
restore them from freezing in a state capable of maintaining
coordinated cardiac contraction and even respiration and conscious
reaction. Other organ systems are also believed to be maintained
with a high degree of biological integrity, i.e., in a
physiological state capable of maintaining life.
[0055] The following examples are offered by way of illustration
and not by way of limitation.
EXPERIMENTAL
[0056] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to carry out the synthesis of the invention and
is not intended to limit the scope of what the inventors regard as
their invention. Efforts have been made to ensure accuracy with
respect to numbers used (e.g., amounts, temperature, etc.), but
some experimental error and deviation should be accounted for.
Unless indicated otherwise, parts are parts by weight, molecular
weight is weight average molecular weight, temperature is in
degrees Centigrade, and pressure is at or near atmospheric.
Example 1
Solution Compositions
[0057] A. Composition of L solution. The composition of L solution
is as follows: Na.sup.+143 mM; Ca.sup.++2.5 mM; Mg.sup.++0.45 mM;
K.sup.+ mM 3.0; Cl.sup.-124 mM; glucose 5 mM; and lactate 28 mM.
The solution is filtered to remove undissolved material and placed
in autoclavable containers and heated in an autoclave to a
temperature of 120.degree. C. for 15 minutes.
[0058] B. Composition of HL (BioTime Hextend.TM.-lactate) Solution.
L formulation with the addition of 60 g/l of high molecular weight
Hetastarch.
[0059] C. Composition of HLB (BioTime
Hextend.TM.-lactate-bicarbonate) Solution. HL solution with the
addition of 5 ml/l 1 M solution of NaHCO.sub.3.
[0060] D. Composition of HL-DL (BioTime Hetadex.TM.-lactate)
Solution. HL formulation except 6% Dextran 40 is used in place of
6% Hetastarch.
[0061] E. Composition of AL (BioTime Albextend.TM.) Solution. L
solution except with the addition of 50 g/l albumin. ALB solution
is AL solution with the addition of 5 ml/l of a 1 M
NaHCO.sub.3.
[0062] F. Composition of HL-Heme Solution. HL solution with the
addition of 20-200 g/l hemoglobin.
[0063] G. Composition of L-Heme Solution. L solution with the
addition of 20-200 g/l hemoglobin.
Example 2
Blood Replacement with HL-DL Solution.
[0064] A 240 g female rat was anesthetized with ketamine, xylazine
an acepromazine mixture injected i.m. The animal was placed on a
stage and its right femoral artery and vein cannulated. The animal
was perfused isovolemically with 10 ml of HL-DL solution until its
hematocrit reached 17.2%. The cannulas were removed, vessels
ligated, and the incision closed. The animal tolerated perfusion
well, and was active and eating within 3 days of the procedure. The
animal recovered fully and remained alive and healthy.
Example 3
Reviving An Ice-Cold Blood-Substituted Dog.
[0065] A 26.8 kg male dog was anesthetized with nembutal and
intubated. It was moved to the operating room, ventilated, and
catheterized with venous, Foley, arterial, and Swan-Ganz catheters,
and after i.v. heparin, its right femoral artery and vein were
cannulated. An esophageal tube was inserted and antacid
administered. Temperature sensors were placed in the esophagus and
the rectum. Methyl prednisolone was injected i.v.
[0066] The animal was wrapped in a cooling blanket, and surface
cooling initiated. The animal's cannulas were connected to a bypass
circuit, which consisted of a vortex blood pump, an oxygenator with
a built-in heat exchanger, a secondary in-line heat exchanger, and
a funnel for the rapid administration of blood and blood
substitute. Whole blood (225 ml) was removed from the dog and saved
for rewarming. Blood volume was quickly replaced with HLB solution.
The bypass circuit containing 1.05 liters of HLB solution was
opened to the animal, and core cooling began.
[0067] Thirty three liters of HLB solution were exchanged. After
substantially all of the blood was removed, a sufficient amount of
a blood 2 M KCl solution was infused to stop cardiac contraction.
By the time the ice-point was approached, the hematocrit was far
below 1%. The animal's deep esophageal temperature was below
10.degree. C. for 4 hours and 5 minutes, with a minimum recorded
temperature of 0.7.degree. C.
[0068] Following the hypothermic period, the animal was warmed.
When body temperature climbed past 10.degree. C., venous effluent
and whole blood previously collected, as well as donor blood, was
returned to the circuit; hematocrit increased with increasing
temperature. Lidocaine and bicarbonate were administered, the heart
defibrillated, and ventilation begun. When blood pressure and body
temperatures approached normal, the animal was weaned from bypass,
and protamine and Lasix injected. Several hours after warm-up, the
animal was conscious and responsive. The animal remained alive and
healthy after the procedure.
Example 4
Reviving an Ice-Cold Blood-Substituted Baboon
[0069] A 24 kg male baboon of the species Papio annubis was
anesthetized first with ketamine and acepromazine i.m., then with
i.v. pentothal. It was then immobilized with pancuronium bromide.
It was intubated, ventilated, and catheterized with venous, Foley,
and arterial catheters. The animal was wrapped in a cooling
blanket, and surface cooling initiated. After i.v. heparin was
administered, the baboon's right femoral artery and bilateral
femoral veins were cannulated. Temperature sensors were placed in
the esophagus, rectum and brain. The animal was instrumented for
EKG, somatosensory evoked potentials (SSEPs) and EEG. Dexamethazone
was injected i.v.
[0070] The animal's cannulas were connected to a bypass circuit,
which consisted of a vortex blood pump, an oxygenator with a
built-in heat exchanger, and a funnel for the rapid administration
of blood and blood substitute. Whole blood (300 ml) was removed
from the baboon and saved for rewarming. The volume was quickly
replaced with 300 ml of physiological saline solution. The bypass
circuit, containing 2 liters of Plasmalyte (commercially available
electrolyte solution), was opened to the animal and core cooling
begun.
[0071] After the deep esophageal temperature declined below
13.degree. C., another 2 liters of Plasmalyte containing 12.5 g of
mannitol, was added to the circuit, replacing the mixture of blood
and Plasmalyte which previously filled the circuit. This diluted
blood was saved for use during warming. Immediately afterwards, 10
liters of HLB solution were added, replacing the Plasmalyte. By the
time the ice-point was reached, the hematocrit was far below 1%.
When the animal reached brain temperature of 3.4.degree. C. and
deep esophageal temperature of 2.8.degree. C., the blood pump was
stopped and the animal was maintained under a condition of
circulatory arrest (standstill) for 45 minutes. After this period,
circulation was resumed.
[0072] Following the hypothermic period, 4.2 liters of HLB solution
were flushed through the animal while collecting venous effluent,
and the animal warmed. When body temperature reached 15.degree. C.,
2 liters of Plasmalyte were added to the circuit to replace the HLB
solution. Mannitol (6.25 g/l) was added to the Plasmalyte in the
circuit. Additionally, venous effluent and whole blood previously
collected, as well as donor blood cells and fresh-frozen plasma,
were returned to the circuit; the animal's hematocrit increased
with increasing body temperature. Another 12.5 g of mannitol were
added to the circuit. When the esophageal and rectal temperatures
approached normal, the heart fibrillated during warming and began
beating. Ventilation was begun. When blood pressure and body
temperatures approached normal, the animal was injected with
protamine i.v., weaned from bypass, its cannulas and catheters
removed, and its incisions closed.
[0073] The animal's deep esophageal temperature had been below
15.degree. C. for 3 hours, and below 10.degree. C. for 2 hours 17
minutes, with a minimum recorded temperature of 2.8.degree. C.
(Table 3). The following morning, the animal was able to sit erect
in its cage and pick up and eat pieces of banana, as well as drink
apple juice. It remained alive and well until sacrificed more than
one week later for histological evaluation.
Example 5
Blood Replacement with Two Solution System in a Patient Undergoing
Cardiopulmonary Bypass Surgery
[0074] A patient is anesthetized, cannulated and instrumented for
cardiopulmonary bypass. The patient is wrapped in a cooling blanket
and surface cooled to 30.degree. C. The patient is then placed on
bypass with the circuit primed with ALB solution. The patient is
core and surface cooled until his deep esophageal temperature
reaches 20.degree. C. Blood is collected with 4 L of ALB solution,
and immediately replaced with HLB solution. The body is then cooled
and maintained while surgical procedures are performed on the heart
or brain. The patient is then warmed, and the HLB solution replaced
first with ALB solution, and then with the ALB-blood solution
originally removed. 5-10 mg of vitamin K is administered.
[0075] One of the advantage of using the ALB solution as a bypass
prime and for blood collection is that when the patient's own
hemodiluted blood is reinfused during warm-up, albumin functions as
the naturally-occurring compound, maintaining blood oncotic agent
without impeding the patient's own ability to synthesize
albumin.
Example 6
Emergency Blood-Substitution of Hemorrhaging Subject with HL-Heme
Solution
[0076] A patient suffering from severe blood loss is infused with
HL solution containing 5 mg/l of blood-clotting factor vitamin K
and 30 g/l of the oxygen-carrying component hemoglobin. The
patient's blood pressure is stabilized and normal oxygen delivery
to the patient's tissues is resumed. The patient's body gradually
clears the Hetastarch component while synthesizing its own albumin
such that blood oncotic pressure remains stabilized during the
recovery period.
[0077] Use of HL solution containing blood-clotting factors and
oxygen-carrying components allows the use of substitute blood to be
reduced or completely avoided.
Example 7
Use of Blood Clotting Factor in Hemodiluted Mammals
[0078] Six young female rats (227-262 g) were anesthetized, their
right femoral arteries and veins cannulated, and 40-60% of their
blood replaced with HL solution. After hematocrits were reduced to
16-22%, the animals were slowly injected i.v. with 6 ml of
Trasylol.RTM. (10,000 KIU/ml). Their tails were severed 30 mm above
the tip. Blood loss averaged 0.39.+-.0.06 (mean.+-.SEM) ml, and all
but one animal survived at least one day. Eight control animals
were similarly perfused with HL solution, but were not given
Trasylol.RTM. injections. The average blood loss was 4.8.+-.0.54
ml, and only 3 of the 8 animals survived. Compared to untreated
controls, mortality (P<0.02) and blood loss (P<0.002) in the
HL-treated animals without Trasylol.RTM. was significantly
greater.
Example 8
Ice-Cold Blood Substitution of a Dog with Solution HLB
[0079] Place a 25-30 Kg dog on partial cardio-pulmonary bypass.
Surface and core cool the dog to near the ice point (1-3.degree.
C.). Replace the dog's blood with solution HLB hypothermic blood
substitute, described in Example 1. Retain the blood for
transfusion during rewarming. Reduce the animal's body temperature
to near the ice point (below 4.degree. C.) and then rewarm. Replace
the blood substitute with blood with warming and revive the
animal.
[0080] Preparation. Catheterize the dog by means of the right
radial vein, injected iv with pentothal, then fit with an
endotracheal tube and ventilate with isofluorane (or Flether) in
100% O.sub.2. Initiate a Ringer's lactate drip at a rate titrated
to the dog's arterial blood pressure (approx. 40 ml/hr iv). Place
the dog on a cooling blanket cooled with recirculating ice water.
Catheterize the right carotid artery to allow for blood pressure
(CAP) monitoring, and add a 3-way stopcock in-line to allow
arterial blood sampling every 10-60 min. throughout the entire
procedure. Insert a foley catheter for urine collection and measure
the urine volume throughout the procedure. Implant a 2 lumen, 7 F,
Swan Ganz wedge catheter via the right jugular vein or right
femoral vein, which is fed through the right heart into the
pulmonary artery. Use the distal port to measure pulmonary wedge
pressure (PAW), the proximal port is used for central venous
pressure (CVP). (If necessary CVP may be measured with a catheter
inserted in one of the brachial veins.) Isolate the left femoral
artery and vein and prepare for cannulation. Heparinize the animal
(approx. 5,000 u). Insert a Biomedicus venous return cannula (15-19
F) in the femoral vein and a Biomedicus arterial cannula (12-15 F)
in the femoral artery. Measure the activated clotting time (ACT)
every 45 min. (until blood substitution) and adjust the heparin
such that it remains greater than 400 sec. Attach a thermocouple
approx. midway to an esophageal tube and insert the unit so that
the tube enters the stomach. A second thermocouple is placed
rectally. Attach ECG leads. Add Solu-Delta-Cortef (Upjohn,
veterinary prednisolone Na succinate), 80 mg by iv injection. Coat
the eyes with Terrimycin (or Lacrylube), and add DiGel (or Maalox,
20 ml) through the esophageal tube.
[0081] Measurements. Measure arterial blood gasses, pH and
hematocrit in every blood sample, and in some cases electrolytes,
enzymes and other chemistries. Monitor esophageal and rectal
temperature as well as the arterial inflow and venous return blood
temperatures. Monitor CAP, PAW, CVP, ECG, and airway pressure.
Temperatures should be displayed digitally and stored as a function
of time in a computerized data acquisition system. The pressures
and ECG should be displayed as real time waveforms or as numerical
data and stored by the computer.
[0082] Bypass Circuit Components. The circuit features a Biomedicus
centrifugal blood pump and flow meter, a Terumo hollow fiber
membrane oxygenator with built-in heat exchanger, Shiley hard shell
venous reservoir with filter and a secondary heat exchanger with
integral bubble trap (Electromedics) located as close to the animal
as possible. A drain segment is located near the inlet of the
venous reservoir and terminates with a check valve. This allows
rapid and efficient blood/blood-substitute exchanges. There is an
A-V shunt segment that allows circulation when not on bypass.
[0083] The venous reservoir can be filled from either the 1 liter
separatory funnel through the "quick prime" port or from dual
infusion bags through one of the cardiotomy ports. The arterial
line from the oxygenator to the arterial cannula and the A-V shunt
are constructed from 1/4" tubing; the venous return, drain and
pump-head lines are 3/8". In those segments where severe bending
can occur, heavy-wall tubing is used or the tube is braced with
"spiral wrap."
[0084] The patient loop is double wrapped and the entire circuit
(sans the factory sterilized reservoir, secondary heat exchanger
and oxygenator) is ethylene oxide gas sterilized as six basic
sections (pump-head, flow meter section, central bypass loop,
funnel, infusion line, and gas filter line).
[0085] Bypass Circuit Support. Ice water, pumped from one of two 10
gal. insulated reservoirs, is used to cool the oxygenator and
secondary heat exchangers. The other reservoir supplies the cooling
blanket. At the onset of surgery, ice water is circulated through
the cooling blanket. At the onset of bypass, room temp. water is
circulated through the circuit heat exchangers.
[0086] Temperature is slowly decreased by adding ice to the
reservoir, in quantities sufficient to maintain a 7-10.degree. C.
difference between the esophageal and blood stream temperatures.
After blood substitution (i.e., to a hematocrit of less than about
4%) full ice water flow is commenced.
[0087] Upon rewarming, ice is removed from the reservoir and the
heater is activated. The temperature of the warming stream is
limited to a maximum of 10.degree. C. greater than the venous
return temperature, by manual adjustment of the heater
thermostat.
[0088] The oxygenator is supplied with sterile, filtered 100%
O.sub.2.
[0089] Blood Substitution. The circuit is primed with 2 liters of
solution L (Example 1), and recirculated through the A-V shunt to
ensure temperature-gas equilibrium. The cannulas are attached to
the arterial and venous lines of the bypass circuit, and the lines
remain clamped. The cooling blanket is wrapped around the patient
who is surface cooled until a deep esophageal temperature of
35.degree. C. is reached.
[0090] The clamps are removed, and bypass is commenced with the
solution L-diluted blood stream at room temperature (approx.
25.degree. C.). At the onset of cooling, gaseous anesthesia is
discontinued, and the dog is managed with 2.5% pentothal.
[0091] The blood stream is gradually cooled until the animal has an
esophageal temperature of 20.degree. C., at which time blood is
removed by clamping the venous return at the reservoir inlet and
draining from the drain segment while L solution is infused. During
this exchange, an additional 2 liters of L solution is added to the
venous reservoir and when the level of L solution drops to 250 ml,
approximately 6 liters of HLB is added stepwise until all of the
blood is removed (HCT less than 2%, visual observation).
Approximately 4 liters of blood/blood-substitute mixtures collected
in sterile bottles and retained for reinfusion. The very dilute
blood mixture (about 51/2 liters) is discarded.
[0092] After 4 liters have been exchanged (i.e., after the addition
of 2 liters of solution L and 2 liters of solution HLB), 20 meq KCl
will be injected via a stopcock on the secondary heat exchanger, to
arrest the heart. During the exchange, the inflow is adjusted such
that the PAW is kept below 5 mm Hg and the rate of efflux equals
the rate of influx, i.e., as close to isovolemia as possible. At
the end of the exchange the final reservoir level will be about 500
ml, the PAW below 5 mm Hg and the CVP less than 5 mm Hg. Flow will
be adjusted such that isovolemia will be maintained (constant
reservoir level and the above pressure levels, i.e., PAW<5 mm Hg
and CVP<5 mm Hg).
[0093] When almost all of the blood is removed (HCT less than 4%,
visual observation), the cooling stream can be reduced to ice water
temperature (filling the reservoir with ice), and the dog rapidly
cooled to its minimum temperature. If the HCT is observed to rise
at any time during cold perfusion, the blood mixture can be removed
by exchanging with 2 to 4 liters of solution HLB by the method
described above.
[0094] During the entire procedure, arterial blood samples are
taken and blood gasses, pH, HCT, and in some cases electrolytes,
and other blood chemistries monitored.
[0095] After about 1-2 hours of blood substituted cooling, the
dog's temperature will be about 1-4.degree. C., and rewarming will
begin. The dog will be rewarmed, by removing the ice from the
supply reservoir and warming its contents with the heater which in
turn warms the blankets. When the esophageal temp reaches
15.degree. C., 4 liters of solution L with 25 g mannitol will be
exchanged with the solution HLB followed by the 4 liters of
collected blood mixture. The effluent will be discarded.
[0096] The animal will be transfused with stored autologous or
donor blood and warmed gently with a warming temperature
differential less than 10.degree. C. and never above 40.degree. C.
The heart will spontaneously begin to beat or will be
defibrillated. When the animal's temperatures (esophageal and
rectal) reach about 35.degree. C., physiological parameters are
stabilized, and it can support itself, it can be weaned from the
extracorporeal circuit.
Example 9
Concentrated Aqueous Solution of Magnesium and Potassium for
Cardioprotection
[0097] The discovery disclosed here is a novel product,
specifically, an aqueous solution consisting of high concentrations
of K.sup.+ and Mg.sup.2+ to be used in conjunction with ice cold
HLB blood substitution in subjects requiring low-temperature
surgery, in subjects requiring cardioplegia, or in organ donors to
better preserve organs--such as hearts--prior to
transplantation.
[0098] This solution can be used in conjunction with hypothermic
total body washout with the HLB solution at cold temperatures to
provide better cardiac protection during periods of circulatory
arrest. The solution can also be used as a cardioplegia agent along
with HLB in standard cardiac surgery procedures not involving total
body washout, or to preserve the heart for transplantation after
total body washout with cold HLB solution.
[0099] In preparing the high concentration solution of Mg and K,
MgSO.sub.4 and KCl have been used. These compounds are currently
available in a form approved for use in human patients by the US
FDA. However, MgCl.sub.2 may substitute for MgSO.sub.4 and KOH may
also be useful in providing a basic pH at about 7.8 (range
7.2-8.4). Other substances which may be used in preparation of the
high concentration solution of K and Mg are KHCO.sub.3,
K.sub.2PO.sub.4, K lactobionate, K citrate, K acetate and K
gluconate, as well as the addition of NaHCO.sub.3 to the solution
containing K.sup.+ and Mg.sup.++. The end result however being a
solution containing approximately 1.5 M potassium and 0.5 M
magnesium.
[0100] Initially, a solution containing 50 mM KCl and 10 mM
MgSO.sub.4 in HLB solution was prepared. Approximately 1 to 2 ml of
this solution was administered iv or intra-arterially to induce
cardiac arrest of a small ice-cold blood substituted hamster. This
volume corresponds to about 30-50% of a blood hamster's blood
volume. It was discovered experimentally that this solution, when
bolused intravascularly just upon completion of total body washout,
induces cardiac arrest.
[0101] It was found that when about 9.5 ml of a 50% solution of
MgSO.sub.4.7H.sub.2O (i.e., approx. 2M) and 27 ml 2M KCl was
administered intra-arterially into ice cold dogs (body weights
about 25 kg, with estimated blood volumes of about 1.8 liters)
whose blood was replaced with HLB, significantly better protection
of the heart resulted compared to that when no additional K and Mg
is administered or when a more diluted K/Mg solution is
administered (i.e., first dissolving the concentrated K/Mg solution
in approximately 500 ml HLB solution in an oxygenator reservoir,
and further diluting the solution in a circuit containing an
additional 850 ml of HLB, which would create a 6.2 mM Mg.sup.++ and
17.4 mM K.sup.+ solution).
[0102] The solution, containing about 37 ml of 0.55M
MgSO.sub.4.7H.sub.2O and 1.48M KCl, was adminstered into a
component of the bypass circuit (heat exchanger) which was directly
connected to the femoral artery of the subject. Based on this dog
experimentation, this solution is expected to provide improved
cardiac protection in subjects whose blood is replaced with HLB at
low temperature.
[0103] Similarly, when delivering 0.1 ml of a high concentration
Mg.sup.++/K.sup.+ mix intra-arterially into hamsters, it
effectively provides cardiac protection when used just after
hypothermic total body washout with HLB.
[0104] The novel discovery described here is the use of a solution
consisting of extremely high concentrations of Mg and K which can
be administered safely and effectively to induce cardioprotection
particularly in conjunction with cold subjects whose blood has been
replaced with HLB. The concentration of K.sup.+ and Mg.sup.++
administered is more than 10 times higher (for both electrolytes)
than previously used or described to protect cold hearts.
[0105] 1. Revival of a hamster using HLB and concentrated Mg/K
solution.
[0106] A 55 g female hamster, fasted overnight was anesthetized
with Ketamine 0.03 ml (100 mg/ml solution) and covered with crushed
ice to lower rectal temperature to about 13.degree. C. The animal
was then placed on a surgical platform under a stereo microscope.
Cannulas were placed in the carotid artery and jugular vein. The
HLB solution was perfused into the artery while venous effluent was
collected. The blood was replaced with ice-cold HLB solution. When
about 65% of the blood was removed, the animal's temperature was
lowered to about 1.degree. C. Ventilation with 100% O.sub.2 was
initiated when the animal's temperature fell below 10.degree. C.
Approximately 7 ml or 2 blood volumes was required to replace most
of the circulating blood. Upon cessation of perfusion, a 0.2 ml
bolus (I.V.) of 0.5M KCl with 0.1M MgSO.sub.4 was given. The heart
arrested immediately. The animal was maintained in cardiac arrest
for 5 hrs and 30 min. The animal was then perfused with 3 ml HLB
followed by blood taken from donor animals. Upon gradual rewarming,
normal heart beat and breathing resumed. On recovery, the animal
demonstrated an ability to respond to stimuli, such as gentle
pressure on the abdomen or paws.
[0107] 2. A 70 g hamster, fasted overnight, was anesthetized with
0.03 ml ketamine (100 mg/ml solution) and covered with crushed ice
to lower rectal temperature to about 13.degree. C. The animal was
then placed on a surgical platform under a stereo microscope.
Cannulas were placed in the carotid artery and jugular vein. The
HLB (with added glucose 50 mM and 5 mM NaHCO.sub.3) solution is
perfused into the artery while venous effluent is collected. The
blood was replaced with ice-cold HLB solution. When about 65% of
the blood was removed the animals temperature was lowered to about
1.degree. C. Ventilation with 100% O.sub.2 was initiated when the
animals temperature fell below 10.degree. C. Approximately, 7 ml or
2 blood volumes is required to replace most available blood.
[0108] A solution consisting of 0.02 ml 1 M MgSO.sub.4 plus 0.1 ml
KCl 1 M is diluted with 0.1 ml HLB. Then the final 0.22 ml solution
is administered iv. This corresponds to delivery of a cocktail 0.5M
KCl and 0.09M MgSO.sub.4. After 5 hours of circulatory arrest the
animal is perfused with 3 ml HLB then blood taken from donor
hamsters. As the animal is warmed, heart beat, breathing, and
responsivity resume.
[0109] Previous to the discovery of using the Mg/K concentrate it
was not possible to repeatedly obtain such results with regard to
revival of hamster after 5 hours of cardiac arrest.
[0110] 3. A 70 g female hamster, fasted overnight, was anesthetized
with Ketamine 0.03 ml (100 mg/ml solution) and covered with crushed
ice to lower rectal temperature to about 13.degree. C. The animal
was then placed on a surgical platform under a stereo microscope.
Cannulas were placed in the femoral artery and jugular vein. The
HLB solution is perfused into the artery while venous effluent is
collected. The blood was replaced with ice-cold HLB solution. When
about 65% of the blood was removed the animals temperature was
lowered to about 1.degree. C. Ventilation with 100% O.sub.2 was
initiated when the animals temperature fell below 10.degree. C.
Approximately, 5 ml was infused. Then 0.2 ml of a cocktail 0.5M KCl
and 0.09M MgSO.sub.4 is administered intra-arterially. Then 1 ml of
HLB was injected to chase the "cardioprotectant" up the circulatory
system and into the tissues. The animal was maintained in
circulatory arrest for 1 hour. Then the animal was perfused with 4
ml HLB and blood from donors while being rewarmed gradually. It was
observed the hamster's heart resumed a normal EKG signal, followed
by spontaneous breathing, responsiveness, consciousness, upright
posture and long term survival.
[0111] Previously, long term survival was only rarely accomplished
in such experiments without use of the K/Mg concentrate.
Example 10
Method for Using HLB Involving Intermittent Perfusion with
Additional Bicarbonate
[0112] During periods of ice-cold blood substitution and
circulatory arrest it was found that certain neurologic recovery
takes longer compared to continuous circulation of HLB solution. In
experiments on hamsters improved results were obtained using both
extra bicarbonate in HLB and/or intermittent perfusion with HLB to
reduce acidosis. This also prevents rigor and improves recovery
especially of brain function as noted by responsivity following
long periods of cardiac arrest in hamsters.
[0113] It has also been found that slow continuous perfusion of
cold HLB blood substituted dogs appears to provide longer periods
of cardiac arrest time than without continuous perfusion.
[0114] In hamsters it was found that additional bicarbonate, 5 mM,
can be helpful at reducing acidosis after long periods of
circulatory arrest.
[0115] 1. A 60 g hamster, fasted, was anesthetized with Ketamine
0.03 ml (100 mg/ml solution) and covered with crushed ice to lower
rectal temperature to about 13.degree. C. The animal was then
placed on a surgical platform under a stereo microscope. Cannulas
were placed in the carotid artery and jugular vein. HLB solution
(with added glucose 50 mM and 5 mM NaHCO.sub.3) was perfused into
the artery while venous effluent was collected. When about 65% of
the blood was removed the animals temperature was lowered to about
1.degree. C. Ventilation with 100% O.sub.2 was initiated when the
animals temperature fell below 10.degree. C. Approximately, 7 ml or
about 2 blood volumes is required to replace most available blood.
The additional 5 mM NaHCO.sub.3 provided a final pH of 8.5. After
perfusion, the heart was stopped with 0.5 ml of 50 mMKCl and 10 mM
MgSO.sub.4. After 4 hours and 40 minutes the animal was re-perfused
with 2 ml HLB followed by perfusion of blood taken from donor
animals. The animal did not recover to breathing and
responsiveness.
[0116] 2. The same experiment was performed as in 1 above except
that an intermittent perfusion of bicarbonate was introduced for 15
minutes 2 hours and 30 minutes after circulatory arrest.
[0117] A 60 g hamster, fasted, was anesthetized with Ketamine 0.03
ml (100 mg/ml solution) and covered with crushed ice to lower
rectal temperature to about 13.degree. C. The animal was then
placed on a surgical platform under a stereo microscope. Cannulas
were placed in the carotid artery and jugular vein. The HLB (with
added glucose 50 mM and 5 mM NaHCO.sub.3) solution was perfused
into the artery while venous effluent was collected. The blood was
replaced with ice-cold HLB solution. When about 65% of the blood
was removed the animals temperature was lowered to about 1.degree.
C. Ventilation with 100% O.sub.2 was initiated when the animals
temperature fell below 10.degree. C. Approximately 7 ml or 2 blood
volumes was required to replace most available blood. Perfused HLB
(containing an additional 50 mM glucose) plus an additional 5 mM
NaHCO.sub.3 which provided a final pH of 8.5. After perfusion, the
heart was stopped with 0.5 ml of 50 mM KCl and 10 mM MgSO.sub.4.
After 2 hours and 30 minutes, the animal was perfused with HLB for
15 minutes (i.e., 2 ml HLB). After 4 hours and 40 min re-perfused
with 2 ml HLB followed by blood from donor animals and warmed. The
animal revived to breathing and responsivity. The time of cardiac
arrest was over 5 hours.
Example 11
Cryoprotective Solutions
[0118] 1. Preparation of Solution
[0119] a. Method 1
[0120] To prepare 50 ml of a 10% glycerol solution in HLB, 0.45 ml
of HLB is poured into a tube. Then 5 ml of 100% glycerol is added.
The solution is shaken and filtered through 0.2 micron filter or
less.
[0121] b. Method 2
[0122] For 1 liter HLB 15% glycerol: Add HES 60 g/l; NaCl 6.72*g/l
bring volume to 1/2 final volume i.e., 500 ml with de-ionized
water. Add and dissolve by shaking one chemical at a time
MgCl.sub.2 0.09 g/l; CaCl.sub.2 0.37 g/l; KCl 0.22 g/l; glucose 0.9
g/l; Na Lactate (60% syrup) 4.03 ml/L; NaHCO.sub.3 0.42 g/l or 0.84
g/l (the additional bicarbonate may help reduce acidity). Bring to
850 ml with de-ionized water. Add 150 ml 100% glycerol. Filter 0.2
u *the amount of NaCl added is adjusted upon accounting for NaCl in
starch note: with 50 mM extra glucose add 9 g/l additional glucose
with shaking
[0123] 1. A cryoprotective solution of 10% glycerol in HLB allows
revival of partially frozen hamsters.
[0124] A 60 g female hamster, fasted overnight was anesthetized
with Ketamine 0.03 ml (100 mg/ml solution) and covered with crushed
ice to lower rectal temperature to about 13.degree. C. The animal
was then placed on a surgical platform under a stereo microscope.
Cannulas were placed in the carotid artery and jugular vein. The
blood was replaced with 2 ml ice-cold HLB solution followed by
cryoprotective solution of HLB plus 10% glycerol. When about 65% of
the blood was removed the animals temperature was lowered to about
1.degree. C. Ventilation with 100% O.sub.2 was initiated when the
animals temperature fell below 10.degree. C. After perfusion of 5
ml of cryoprotective solution, the heart was arrested with 50 mMKCl
and 10 mM MgSO.sub.4 (1.5 ml i.v.). Animals were then placed in a
plastic bag and immersed in a cooling bath set at -15.degree. C.
After 30 minutes rectal temperatures dropped as cold as
-2.2.degree. C.
[0125] The animal was thawed, reperfused with HLB and then with
donor blood. Upon rewarming, normal EKG signals are observed
followed by breathing and responsiveness. Massive and extensive
lesions (micro-hemorrhages) were observed in the brain upon
necropsy demonstrating that the brain was substantially frozen
under these conditions. However, despite freezing animals can
recover to responsiveness.
[0126] 2. Cryoprotective solution of 10% glycerol and 10% DMSO
[0127] A 60 g female hamster, fasted overnight was anesthetized
with Ketamine 0.03 ml (100 mg/ml solution) and covered with crushed
ice to lower rectal temperature to about 13.degree. C. The animal
was then placed on a surgical platform under a stereo microscope.
Cannulas were placed in the carotid artery and jugular vein. The
blood was replaced with 1.5 ml ice-cold HLB solution followed by
cryoprotective solution of HLB plus 10% glycerol and 10% DMSO. When
about 65% of the blood was removed the animals temperature was
lowered to about 1.degree. C. Ventilation with 100% O.sub.2 was
initiated when the animals temperature fell below 10.degree. C.
After about 6.5-7.0 ml of cryoprotective solution was perfused and
the heart was arrested with 50 mMKCl and 10 mM MgSO.sub.4 (1.5 ml
i.v.) The animals were placed in a plastic bag and immersed in a
cooling bath set at -15.degree. C. After 30 minutes rectal
temperatures dropped as cold as -1.5.degree. C.
[0128] Upon thawing and reperfusion with HLB followed by donor
blood, normal heart beat, breathing and responsiveness resumed.
Massive and extensive lesions were observed in the brain upon
necropsy demonstrating that the brain was substantially frozen
under these conditions and that despite freezing animals can
recover to responsiveness.
[0129] All publications and patent applications cited in this
specification are herein incorporated by reference as if each
individual publication or patent application were specifically and
individually indicated to be incorporated by reference. The
citation of any publication is for its disclosure prior to the
filing date and should not be construed as an admission that the
present invention is not entitled to antedate such publication by
virtue of prior invention.
[0130] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, it is readily apparent to those of ordinary skill
in the art in light of the teachings of this invention that certain
changes and modifications may be made thereto without departing
from the spirit or scope of the appended claims.
* * * * *